Shilpa Medicare Ltd

Shilpa Medicare has at its meeting held today 06 October 2025, accorded approval for the allotment of 9,77,90,908 equity shares of Re 1 each as fully paid-up bonus equity shares in the ratio of 1:1 (i.e., one new bonus equity share of Re 1 each for every one existing equity share of Re 1 each) to the shareholders of the Company as on the Record Date, i.e., 03 October 2025. Consequent to the said allotment, the issued, subscribed and paid-up equity share capital of the Company has increased to 19,55,81,816 equity shares of Re 1 each. Powered by Capital Market - Live

This application, submitted as a hybrid application via the EMA's Centralized Procedure, is a generic version of the innovator product Xarelto, from Bayer AG, which is available as oral tablets. Shilpa Medicare's product is bioequivalent to the reference product Xarelto and is the only Rivaroxaban in ODF form which can help in patient comfort, especially in geriatric patients. Rivaroxaban Orodispersible Films is an anticoagulant medicine (a medicine that prevents blood clotting). It is used to treat deep vein thrombosis and pulmonary embolism, and to prevent their recurrence in adults. It is also used to prevent atherothrombotic events (such as heart attack, stroke or death from heart disease) in adults. It works by inhibiting a highly selective, direct factor Xa. The total Europe market for oral Rivaroxaban formulations is about $2.5 billion. This approval has come from the company's finished dosage form manufacturing facility, Shilpa Medicare, Unit VI, located at Dabaspet, Bengaluru, Karnataka. The facility is currently approved by USFDA, Europe and MHRA UK. This is the third approval of a prescription oral mouth dissolving film product in the European markets from this facility. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving films and transdermal patches. Shilpa Medicare is a manufacturer of API, formulation, and development services. The company's consolidated net profit surged to Rs 46.89 crore in the quarter ended June 2025 as against Rs 14.06 crore during the previous quarter ended June 2024. Sales rose 9.90% to Rs 321.46 crore in Q1 FY26 as compared with Q1 FY25.Powered by Capital Market - Live

The new JV entity would be based in the Kingdom of Saudi Arabia. Leveraging their respective strengths, PPI will contribute its local market expertise, while the Shilpa Group will provide global R&D, manufacturing, and regulatory capabilities. The new limited liability company will be majority owned by PPI (70%), with Koanna holding a 30% stake. The venture represents a significant step in Saudi Arabia's healthcare infrastructure and aligns with the Kingdom's Vision 2030 goals of economic diversification and localizing strategic industries. The partnership will be executed in two key phases to ensure a swift market entry and a robust long-term manufacturing strategy. In the first phase, Shilpa Group will supply finished products in bulk for repackaging at the new JVC's facility. This ensures a rapid market entry for key products. Concurrently, PPI will be responsible for establishing this fully-equipped manufacturing facility with technical input from Shilpa Group. In phase-2, Shilpa Group will execute a full technology transfer of its manufacturing processes to the JV. This will empower the JV to commence local production of finished products. As part of the agreement, Shilpa Group will provide technical support for the transfer of the project site to the JVC. PPI will be responsible for equipping the facility with all necessary infrastructure and packaging equipment to meet international standards. Shilpa Group will be responsible for preparing the complete regulatory registration dossier in compliance with the Saudi Food and Drug Authority (SFDA) and will lead the process of obtaining the necessary market authorization. Vishnukant Bhutada, MD of Shilpa Medicare, said: We are excited to partner with PPI, this JV combines PPI's unmatched local strength with Shilpa's innovative technology to improve healthcare in the Kingdom. PPI is the ideal partner to make our products more accessible. This JV underscores our commitment to Saudi Arabia and will consolidate our presence across the MENA region. Shilpa Medicare is a manufacturer of API, formulation, and development services. The company's consolidated net profit surged to Rs 46.89 crore in the quarter ended June 2025 as against Rs 14.06 crore during the previous quarter ended June 2024. Sales rose 9.90% to Rs 321.46 crore in Q1 FY26 as compared with Q1 FY25. The scrip rose 0.52% to currently trade at Rs 827.75 on the BSE. Powered by Capital Market - Live

Koanna International FZ LLC, UAE (Koanna), a wholly owned subsidiary of Shilpa Medicare, has entered into a definitive agreement with Pharma Pharmaceutical Industries & Biological Products (PPI), a prominent Saudi enterprise to form a new joint venture company based in the Kingdom of Saudi Arabia to build a new pharma manufacturing facility in Saudi Arabia. Under the terms of the JV, Koanna will supply finished formulations in bulk form in phase 1 and in phase 2 carry out technology transfer for manufacturing formulations and enable local production. Shilpa Group will be responsible for preparing the complete regulatory registration dossier in compliance with the Saudi Food and Drug Authority (SFDA) and will lead the process of obtaining the necessary Market Authorization. Powered by Capital Market - Live

Shilpa Medicare announced that the 38th Annual General Meeting(AGM) of the company will be held on 23 September 2025.Powered by Capital Market - Live

Net profit of Shilpa Medicare rose 233.50% to Rs 46.89 crore in the quarter ended June 2025 as against Rs 14.06 crore during the previous quarter ended June 2024. Sales rose 9.90% to Rs 321.46 crore in the quarter ended June 2025 as against Rs 292.51 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales321.46292.51 10 OPM %28.2823.93 - PBDT78.5055.79 41 PBT49.5828.68 73 NP46.8914.06 233 Powered by Capital Market - Live

Shilpa Medicare announced that its wholly-owned material subsidiary, Shilpa Pharma Lifesciences, has fully redeemed its outstanding senior, secured, rated, unlisted, and redeemable Non-Convertible Debentures (NCDs) on 11 August 2025. Accordingly, there are no outstanding NCDs as on date with Shilpa Pharma Lifesciences. Powered by Capital Market - Live

The approval reinforces Shilpa Medicare's commitment to addressing unmet medical needs in hepatology through innovation and evidence‐based solutions. This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD. NorUDCA is the first‐in‐class treatment for non‐alcoholic fatty liver disease (NAFLD) in India, addressing a significant unmet medical need. NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the world's population (approximately 1.2 billion people) and impacting an estimated 188 million individuals in India alone. If not managed early, NAFLD may progress to non‐alcoholic steatohepatitis (NASH) and severe liver complications, underscoring the urgent necessity for effective therapy. These results collectively demonstrate a significant improvement in both liver structure and function, confirming NorUDCA's superior efficacy compared to placebo in NAFLD. Vishnukant Bhutada, managing director, Shilpa Medicare, said: We are delighted to receive historic approval for NorUDCA, India's first‐in‐class therapy for NAFLD'making Shilpa the first company globally to obtain approval for NorUDCA in this indication. This milestone is a moment of immense pride for Shilpa and the nation, as we now pioneer the launch of its finished dosage form. This breakthrough exemplifies Shilpa's unwavering dedication to innovation and accessible healthcare to millions battling liver disease in India and beyond. We are excited to introduce NorUDCA tabletsin India immediately, while advancing global regulatory efforts to bring this vital therapy to patients internationally.' Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company's consolidated net profit fell 40.77% to Rs 14.51 crore, while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24. The scrip had advanced 1.46% to end at Rs 831.80 on the BSE on Friday. Powered by Capital Market - Live

Shilpa Medicare announced the approval of its, Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, by  the Central Drugs Standard Control Organization (CDSCO), marking a major milestone in innovative  Non Alcoholic Fatty Liver Disease (NAFLD) therapy  in India.  The approval reinforces Shilpa Medicare'fs commitment to addressing unmet medical needs in hepatology  through innovation and evidence']based solutions. This approval will allow Shilpa to become the first company in  the World to launch this novel product in any part of the World for NAFLD.  NorUDCA is the first']in']class treatment for Non']alcoholic Fatty Liver Disease (NAFLD) in India, addressing a  significant unmet medical need. Powered by Capital Market - Live

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live